CyDex, Inc. and Bristol-Myers Squibb Team Up for Drug Delivery Solution

CyDex, Inc. (Overland Park, KS) and Bristol-Myers Squibb Company (Princeton, NJ) recently announced the signing of an agreement in which Bristol-Myers Squibb will be allowed to use CyDex's Captisol sulfobutylether beta-cyclodextrin drug delivery technology in the development of a new anticancer compound as well as other potential Bristol-Myers Squibb projects. Captisol is a complexing agent that improves the solubility of specific compounds, thus allowing more efficient delivery of medications.

CyDex is a leader in drug formulation technologies aimed at improving the solubility of medications in the bloodstream by using compounds known as anionically charged sulfobutylether-cyclodextrins.

Bristol-Myers Squibb is a worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices.

For more information: Karl Strohmeier, CyDex, Inc. Tel: 913-685-8850.